Skip to search formSkip to main contentSkip to account menu

GP2013

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Background Biosimilars are innovative therapeutic drugs which offer a cheaper alternation for biological which used for… 
2019
2019
Comparable clinical efficacy of the rituximab (RTX) biosimilar GP2013 and reference RTX has been established in blinded… 
Highly Cited
2017
Highly Cited
2017
Objectives The aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar… 
2016
2016
Background GP2013 has been developed as a proposed biosimilar to originator rituximab (RTX), by Sandoz, a Novartis Company. The… 
2014
2014
Abstract Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here… 
Highly Cited
2013
Highly Cited
2013
BackgroundRegulatory approval for a biosimilar product is provided on the basis of its comparability to an originator product. A… 
2013
2013
3075 Background: Development of a biosimilar involves extensive characterization of the originator product and a target-directed…